| 000 -LEADER |
|---|
| fixed length control field |
04208nam a22004455i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20140310150640.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
120423s2012 xxu| s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9781441959553 |
|
978-1-4419-5955-3 |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RS1-441 |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
615.1 |
| Edition number |
23 |
| 264 #1 - |
|---|
| -- |
New York, NY : |
| -- |
Springer New York, |
| -- |
2012. |
| 912 ## - |
|---|
| -- |
ZDB-2-SME |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Tabrizi, Mohammad A. |
| Relator term |
editor. |
| 245 10 - IMMEDIATE SOURCE OF ACQUISITION NOTE |
|---|
| Title |
Development of Antibody-Based Therapeutics |
| Medium |
[electronic resource] : |
| Remainder of title |
Translational Considerations / |
| Statement of responsibility, etc |
edited by Mohammad A. Tabrizi, Gadi G. Bornstein, Scott L. Klakamp. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
XIV, 425p. 58 illus., 30 illus. in color. |
| Other physical details |
online resource. |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Translational Strategies for Development of Antibody-Based Therapeutics: An Overview -- Discovery Process for Antibody-Based Therapeutics -- Technologies for the Generation of Human Antibodies -- Application of Antibody Engineering in the Development of Next Generation Antibody-Based Therapeutics -- Biophysical Considerations -- Considerations in Establishing Affinity Design Goals -- BioAnalytical Considerations: Pharmacokinetics and Immunogenicity -- Antibody-Based Therapeutics in Oncology : Preclinical Considerations -- Factors Impacting the Tumor Localization and Distribution -- Antibody-Based Therapeutics: Preclinical Safety Considerations -- Application of Pharmacokinetic/Pharmacodynamic Modeling -- Design of Translational Strategies : Application of Population Pharmacokinetic-Pharmacodynamic (PK-PD) Approaches -- Translational Biomarkers: Essential Tools in Development of Antibody-Based Therapeutics -- Development of Antibody-Based Therapeutics: Translational Research in Alzheimer’s Disease -- Considerations in Manufacturing Process Development -- Next Generation Antibody-Based Therapeutics -- Immune Complex Therapies for Treatment of Immune Thrombocytopenia (ITP) -- Application of Bioinformatics Principles for Target Evaluation -- Concluding Remarks. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc |
Development of Antibody-Based Therapeutics: Translational Considerations examines important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics. Translational strategies for development of antibody-based therapeutics require an understanding of the relationship between the ‘unit dose’ and ‘unit effect’ with respect to both beneficial and deleterious biological effects from early stages of development. The flow of information across various stages of development should provide opportunities to facilitate selection of more effective novel and next-generation drug candidates. Successful strategies for the development of monoclonal antibodies require integration of knowledge with regards to target antigen properties in health and disease, as well as antibody design criteria including affinity, isotype selection, pharmacokinetics/pharmacodynamics (PK/PD) properties, antibody cross-reactivity across species, and safety. Selection and evaluation of appropriate biomarkers in early preclinical development in “relevant” animal models should allow identification of potential risks and liabilities of an antibody drug candidate to humans and establishment of safe First-In-Human (FIH) dosing strategies. This volume provides a comprehensive review of the topics critical for establishing successful translational strategies for the development of antibody-based therapeutics. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Pharmacy. |
|
|---|
| Topical term or geographic name as entry element |
Toxicology. |
|
|---|
| Topical term or geographic name as entry element |
Biochemistry. |
|
|---|
| Topical term or geographic name as entry element |
Pharmacy. |
|
|---|
| Topical term or geographic name as entry element |
Pharmacy. |
|
|---|
| Topical term or geographic name as entry element |
Pharmacology/Toxicology. |
|
|---|
| Topical term or geographic name as entry element |
Biochemistry, general. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Bornstein, Gadi G. |
| Relator term |
editor. |
|
|---|
| Personal name |
Klakamp, Scott L. |
| Relator term |
editor. |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY |
|---|
| Title |
Springer eBooks |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Display text |
Printed edition: |
| International Standard Book Number |
9781441959539 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
http://dx.doi.org/10.1007/978-1-4419-5955-3 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
|
| Item type |
E-Book |
